Fig. 1
Tivantinib inhibits HCC cells proliferation independent of their MET status. a Western blot analysis was performed to detect the expression profile of MET in HCC cells. (b, c and d) Cytotoxicity assay. HCC cells were treated with different concentration of tivantinib, JNJ-38877605 and PHA-665752 for 72 h. IC50 was calculated by nonlinear regression analysis using GraphPad Prism software